Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
A legfontosabb adatok
- Ki végzi
- Icahn School of Medicine at Mount Sinai
- Hol
- New York (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 10 fő vett részt
- Kezdés
- 2021. aug. 31.
- Befejezés
- 2025. jan. 29.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Medical Device Usage and Evaluation
- CT simulation
- Stereotactic body radiation therapy
- Brachytherapy
- Post-implant dosimetry scan
- A regiszteradat frissítve
- 2025. február 26.
- Miért állt le
- Was not meeting target enrollment; other treatment options precluded completing study
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically/biopsy confirmed adenocarcinoma of prostate within 1 year of registration
- Disease confined to the prostate. Prostate volume must be <150cc confirmed by pelvic CT (with or without contrast) or pelvic/prostate MRI (with or without contrast) +/- ultrasound, within 8 months of signing research consent
- Age >18
- Patients deemed medically suitable to undergo rectal spacer placement, external beam radiotherapy and brachytherapy at the discretion of the radiation oncologist, urologist, medical oncologist and/or internist
- ECOG score of 0-2
- One or more of the following risk factors for intermediate risk prostate cancer; T2b or T2c clinical stage, GS 7 (either 3+4 or 4+3), PSA 10-20
- Ability to understand and the willingness to sign a written informed consent
- PSA result within 6 months of simulation
Ki nem vehet részt
- Patients who have undergone previous rectal, bowel, bladder, or prostate surgeries in the past
- Patients with previous treatments for their prostate cancer or that are currently receiving any other experimental therapies
- Patients who have undergone prior pelvic radiotherapy
- Patients receiving antiandrogen therapy (ADT)
- Patients with any prior active or treated genitourinary malignancy
- Patients with disease not confined to the prostate based on imaging, biopsy, or clinical exam
- Patients with high risk prostate cancer that have any of the following risk factors; GS >= 8, PSA > 20, clinical or imaging stage T3a or higher
- Patients with a prostate size > 100 cc based on computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound measurements
Helyszínek itt: Egyesült Államok
- Mount Sinai HospitalNew York, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase II trial studies the effect of rectal spacer hydrogel before radiation therapy in reducing radiation dose to the rectum in patients with prostate cancer. Rectal spacer hydrogen is a soft gel material used to create a space between the rectum and prostate during radiation treatment. The rectal spacer gel is made up of 90% water and 10% polyethylene glycol and is injected as a liquid through a needle inserted between the rectum and prostate. It stays in place for about 3 months and is naturally absorbed into the body and removed through urine in about 6 months. By pushing the prostate further from the rectum with the hydrogel, it may help spare the rectum from receiving radiation during standard of care stereotactic body radiation therapy and brachytherapy treatment.
A vizsgálat csoportja
- Patients with prostate cancerA vizsgált kezelés
Patients undergo hydrogel rectal spacer placement on day 1. Within 2 weeks (+/-1 week) after Rectal Spacer placement, patients will be scheduled for CT simulation for external beam treatment planning. Patients will begin the SBRT of 24Gy in 5 fractions within 2 weeks (+/-1 week) from the simulation date. Within 4 weeks (+/-1 week) of last day of SBRT, patients undergo brachytherapy. Patient will return for post-implant CT-based dosimetry analysis 4 weeks (+/- 1 week) post brachytherapy,
Kezelés: Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy, Brachytherapy és Post-implant dosimetry scan
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Non-Randomized Phase II Study of the Reduction in Rectal V100 With the Use of Rectal Spacer Hydrogel in the Management of Intermediate Risk Prostate Cancer Treated With Combined Modality Radiation Therapy
- A regiszteradat frissítve
- 2025. február 26.